In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Olive oil consumption can favorably affect cardiovascular prognosis in patients after percutaneous coronary intervention

Session Poster session 3

Speaker Evangelos Oikonomou

Event : ESC Congress 2015

  • Topic : preventive cardiology
  • Sub-topic : Nutrition, Malnutrition and Heart Disease
  • Session type : Poster Session

Authors : E Oikonomou (Athens,GR), G Siasos (Athens,GR), M Zaromytidou (Athens,GR), S Tsalamandris (Athens,GR), K Mourouzis (Athens,GR), M Anastasiou (Athens,GR), E Dimitropoulos (Athens,GR), K Zisimos (Athens,GR), K Maniatis (Athens,GR), D Tousoulis (Athens,GR)

Authors:
E. Oikonomou1 , G. Siasos1 , M. Zaromytidou1 , S. Tsalamandris1 , K. Mourouzis1 , M. Anastasiou1 , E. Dimitropoulos1 , K. Zisimos1 , K. Maniatis1 , D. Tousoulis1 , 1University of Athens Medical School, 1st Cardiology Department, “Hippokration” Hospital - Athens - Greece ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 475

Background: Mediterranean diet has been associated with favorable cardiovascular effects.

Purpose: To examine the association between different dietary patterns with the prognosis of patients with coronary artery disease (CAD)after percutaneous coronary intervention (PCI).

Methods: We followed up prospectively (median time: 40 months), 220 subjects with stable CAD one month after successful PCI. Several demographic and clinical characteristics were collected. All subjects were tested with a validated semi quantitative food frequency questionnaire. Principal components analysis was used in order to evaluate the relationship between dietary habits and the prognosis of CAD. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or hospitalization for cardiovascular causes.

Results: During the follow-up period 66 subjects presented the primary composite endpoint. There was no difference in age (p=0.54), serum creatinine levels (p=0.50), body mass index (p=0.84),diabetes mellitus (p=0.33) and hypertension (p=0.54), between the subjects who presented the primary end point compared to subjects free of cardiovascular events. Interestingly, subjects who presented the primary end point compared to those free of cardiovascular events were more often active smokers (28% vs. 15%, p=0.03), had higher prevalence of 3 vessel CAD (p=0.03) and lower left ventricle ejection fraction (p=0.07). A cox regression model revealed that after adjustment for the aforementioned confounders 3VD was associated with adverse cardiovascular outcome (Hazard ratio=3.14 95% CI: 1.19–8.27, p=0.02). Interestingly, when in the model was added a favorable pattern of diet (revealed by principal components analysis) it was observed that high consumption of olive oil and low consumption of seed oil or animal or vegetable fats reduce the hazard of adverse cardiovascular outcome (Hazard ratio=0.70 95% CI: 0.49–0.99, p=0.047).

Conclusions: In subjects with CAD after PCI a favorable pattern of diet with increased consumption of olive oil and low consumption of seed oil or animal or vegetable fats can decrease the hazard of adverse cardiovascular outcome.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are